We, as individuals, have a natural tendency to be cautious, so we are always looking for that selling pitch to convince us about different things. This selling pitch decides whether or not we’ll be devoting our attention and possibly resources to the subject in question. Now, at times, we can also make errors with our interpretation of said marketing efforts, but fortunately, we have a proven ability to be able to recover quickly. Such adaptability sets up a campaign for our own skills, which as per the evidence, are diverse beyond anything. Nevertheless, it wasn’t always the case. Throughout the history, we have dabbled around and enhanced our skill-set in a rather step-by-step manner. By doing so, we have been able to grow in a sustainable and inclusive way, something that will never cease to benefit us. You see, the trajectory in play here has so far guided the world towards a whole host of milestones. While each one added to our lives under some capacity, the one that stands tall as our most prominent milestone to this day is technology. In a way, technology turned up as the culmination of a very long cycle. All our experiences and lessons happened to be embedded bone-deep into this ingenious creation, and the result was as fascinating as you would imagine. However, despite the big step up, we have continued to make inventive runs for a better reality, and some recent events in the pharmaceutical industry suggest that we might just witness another one, as the sector ramps up its focus on a highly significant aspect.
Omnicell has officially acquired ReCept Pharmacy in a deal reported to be around the sum of $100 million. The acquisition is being considered as Omnicell’s attempt to enter the specialty pharmacy sphere, an area which has shown signs of growing exponentially over the next few years. With everything signed, sealed, and delivered, the company will now be able to access ReCept’s cutting-edge medication management technologies for handling specialty drugs that include biologics often prescribed through infusions and injections. Specialty drugs are a challenge to handle and administer optimally for a lot of reasons. The nature, scale, and supporting capabilities all get to play an important part in this context. However, ReCept’s impressive track record in serving federally qualified health centers, healthcare provider groups, and general health systems etc offers Omnicell a well-constructed path to make a difference.
“As medical innovations drive new, more complex drugs, pharmacy requires more specialized tools and expertise to help manage the patient’s treatment journey,” said Randall Lipps, CEO of Omnicell. “The ReCept acquisition is a strategic investment that expands our portfolio to address the significant market need for specialty pharmacy solutions.”
The financial prospects of expanding your presence in specialty drugs management are huge. In 2020, the discipline had 51% of all pharma sales to its name, the figure roughly translating to sales worth $269 billion. By adding ReCept to its own solid setup that helps pharmacies with hardware and software for managing medication, Omnicell has now everything in place to take over the modern pharmaceutical landscape.
